Alalfi Mohammed O, Lanzino Giuseppe, Flemming Kelly D
Departments of1Neurologic Surgery and.
2Neurology, Mayo Clinic, Rochester, Minnesota.
J Neurosurg. 2023 Mar 17;139(4):1018-1024. doi: 10.3171/2023.1.JNS222434. Print 2023 Oct 1.
Newly diagnosed patients with a familial cavernous malformation (FCM) and their families are concerned about their future outlook, which is scarcely discussed in the literature. The authors studied a prospective contemporary cohort of patients with FCMs to assess demographics, mode of presentation, prospective risk of hemorrhage and seizures, need for surgery, and functional outcome over an extended interval.
A prospectively maintained database beginning January 1, 2015, of patients diagnosed with a cavernous malformation (CM) was queried. Data on demographics, radiological imaging, and symptoms at first diagnosis were collected in adult patients who gave their consent to prospective contact. Follow-up was done using questionnaires, in-person visits, and medical record review to assess for prospective symptomatic hemorrhage (i.e., the first hemorrhage after enrollment in the database), seizure, functional outcome measured by the modified Rankin Scale (mRS), and treatment. The prospective hemorrhage rate was calculated by the number of prospective hemorrhages divided by patient-years of follow-up censored at last follow-up, first prospective hemorrhage, or death. A Kaplan-Meier curve of survival free of hemorrhage was obtained comparing patients with versus without hemorrhage at the time of presentation and compared with a log-rank test for p < 0.05.
A total of 75 patients with FCM were included, of whom 60% were female. The mean age at diagnosis was 41 ± 16 years. Most symptomatic or large lesions were located supratentorially. At first diagnosis, 27 patients had no symptoms, and the remaining were symptomatic. Over an average of 9.9 years, the rate of prospective hemorrhage was 4.0% per patient-year, and the rate of new seizure was 1.2% per patient-year, with 64% and 32% of patients experiencing at least one symptomatic hemorrhage and at least one seizure, respectively. Thirty-eight percent of the patients underwent at least 1 surgery and 5.3% underwent stereotactic radiosurgery. At the last follow-up, 83.0% of patients remained independent with an mRS score ≤ 2.
The authors' findings provide clinically useful information on hemorrhage rate, seizure rate, the likelihood of surgery, and functional outcome. These findings can be helpful to practicing physicians when counseling patients with FCM and their families, who are often apprehensive about their future and well-being.
新诊断的家族性海绵状血管畸形(FCM)患者及其家属关心其未来前景,而这在文献中鲜有讨论。作者对一组前瞻性的FCM患者当代队列进行研究,以评估其人口统计学特征、表现方式、出血和癫痫发作的前瞻性风险、手术需求以及较长时间内的功能结局。
查询了一个自2015年1月1日起前瞻性维护的诊断为海绵状血管畸形(CM)患者的数据库。收集了同意接受前瞻性随访的成年患者的人口统计学数据、放射影像学资料及首次诊断时的症状。通过问卷调查、门诊访视及病历审查进行随访,以评估前瞻性症状性出血(即纳入数据库后的首次出血)、癫痫发作、用改良Rankin量表(mRS)测量的功能结局及治疗情况。前瞻性出血率通过前瞻性出血次数除以上次随访、首次前瞻性出血或死亡时的患者随访人年数来计算。获得了出血-free生存的Kaplan-Meier曲线,比较了就诊时有出血和无出血的患者,并通过对数秩检验得出p<0.05。
共纳入75例FCM患者,其中60%为女性。诊断时的平均年龄为41±16岁。大多数有症状或较大的病变位于幕上。首次诊断时,27例患者无症状,其余有症状。平均随访9.9年,前瞻性出血率为每年4.0%,新发癫痫发作率为每年1.2%,分别有64%和32%的患者经历至少一次症状性出血和至少一次癫痫发作。38%的患者至少接受了1次手术,5.3%的患者接受了立体定向放射外科治疗。在最后一次随访时,83.0%的患者mRS评分≤2,仍为独立状态。
作者的研究结果提供了关于出血率、癫痫发作率、手术可能性及功能结局的临床有用信息。这些结果有助于执业医师为FCM患者及其家属提供咨询,他们通常对自己的未来和健康状况感到担忧。